TELA Bio Inc (TELA) FinancialsTELATELA Bio Inc

TELA Bio Inc (TELA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is OviTex, accounting for 69.0% of total sales, equivalent to $13.31M. Other significant revenue streams include OviTex PRS and Other. Understanding this composition is critical for investors evaluating how TELA navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, TELA Bio Inc maintains a gross margin of 69.17%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -51.23%, while the net margin is -58.38%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively TELA converts its operational activities into shareholder value.

In the context of the broader market, TELA competes directly with industry leaders such as CVRX and NEPH. With a market capitalization of $37.92M, it holds a leading position in the sector. When comparing efficiency, TELA's gross margin of 69.17% stands against CVRX's 87.39% and NEPH's 58.45%. Such benchmarking helps identify whether TELA Bio Inc is trading at a premium or discount relative to its financial performance.

TELA Bio has shown a gross margin of 69.17% in Q2 2026, indicating strong profitability on sales, yet it continues to report substantial net losses, with a net margin of -58.38%.